Market News / Story
Zealand, Roche release phase 2 topline data for amylin analogue petrelintide
Seeking Alpha ·
Seeking Alpha reports: Zealand Pharma said that topline phase 2 results for its amylin analogue petrelintide showed that the candidate achieved significant weight reduction and A1C improvement compared to placebo. The ZUPREME-2 trial enrolled 220 individuals who are overweight or obese and have type 2 diabetes. Subcutaneous injections were given weekly, with those in the two petrelintide arms having their dosage increased every four weeks. Results showed that after 28 weeks, those in the…